Gvoke VialDx is a concentrated liquid glucagon product. For diagnostic procedures, it works as a gastrointestinal motility inhibitor. The product is supplied as a single-dose vial containing 1mg of ...
Xeris Biopharma Holdings has received regulatory approval for a new use of its Gvoke liquid glucagon in gastrointestinal ...
Holdings announced that its supplemental new drug application, sNDA, of Gvoke VialDx has received U.S Food and Drug ...
Zacks.com on MSN5d
Strength Seen in Xeris Biopharma (XERS): Can Its 5.6% Jump Turn into More Strength?Xeris Biopharma (XERS) witnessed a jump in share price last session on above-average trading volume. The latest trend in ...
Xeris also announced it has partnered with American Regent to commercialize Gvoke VialDx. Under the terms of the agreement, Xeris will be responsible for product supply, and American Regent will ...
We recently published a list of 12 Best Stocks to Invest in for a Stock Market Game. In this article, we are going to take a ...
InvestingPro analysis reveals 8 additional key insights about the company’s potential. Gvoke VialDx™ is designed to temporarily inhibit gastrointestinal movement during diagnostic procedures ...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of ...
CHICAGO - Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a $742 million market cap pharmaceutical company whose stock has surged 116% over the past year, has announced the FDA approval of its ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback